Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022.

Authors :: Huiberts AJ
de Gier B
Hoeve CE
de Melker HE
Hahné SJ
den Hartog G
van de Wijgert JH
van den Hof S
Knol MJ
Source :: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2023 Feb; Vol. 28 (7).
Publication Year :: 2023
Abstract: We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.

Subjects :: Humans
Netherlands epidemiology
Prospective Studies
SARS-CoV-2 genetics
RNA, Messenger
Vaccination
COVID-19 prevention & control

Language :: English
ISSN :: 1560-7917
Volume :: 28
Issue :: 7
Database :: MEDLINE
Journal :: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Publication Type :: Academic Journal
Accession number :: 36795500
Full Text :: https://doi.org/10.2807/1560-7917.ES.2023.28.7.2300087

Full Text Access

Tools